CAS: 81093-37-0; (3R,5R)-3,5-Dihydroxy-7-((1S,2S,6S,8S,8Ar)-6-Hydroxy-2-Methyl-8-(((S)-2-Methylbutanoyl)Oxy)-1,2,6,7,8,8A-Hexahydronaphthalen-1-yl)Heptanoic Acid

该化合物是国家药物类药物的成员,主要用于降低血液胆固醇水平和减少心血管疾病的风险,它作为HMG-CoA再生酶抑制剂,这是胆固醇生物合成途径中的关键酶.pravastatin的化学配方为C23H35NaO7, 其特点是其特定结构特征,包括一种增强溶性,生物利用率的氢氧化酸碱.普拉瓦斯坦因通常以口服形式施用,并因其相对相对有利的副作用而著称,它具有相对有利的副作用,还具有提高内皮功能和产生抗炎作用的能力,而且该物质通常为高脂性贫血病人或可能患有血清活性心血管疾病的病人开具处方.与所有药物一样,在治疗期间,监测潜在相互作用和副作用至关重要.

结构式图片

欧盟法规

C&L通报

上下游产品

3,5-bis-epi-compactin mevastatin pravastatin sodium saltpravastatin lactone (S)-2-Methyl-butyric acid (1S,3R,4aS,7S,8S,8aS)-8-[(3R,5S)-7-(tert-butyl-diphenyl-silanyloxy)-3,5-dihydroxy-heptyl]-3-hydroxy-7-methyl-decahydro-naphthalen-1-yl ester (S)-2-Methyl-butyric acid (1S,4aS,7S,8S,8aS)-8-(2-{(4R,6S)-6-[2-(tert-butyl-diphenyl-silanyloxy)-ethyl]-2,2-dimethyl-[1,3]dioxan-4-yl}-ethyl)-7-methyl-3-oxo-decahydro-naphthalen-1-yl ester (S)-2-Methyl-butyric acid (1S,3R,4aS,7S,8S,8aS)-8-(2-{(4R,6S)-6-[2-(tert-butyl-diphenyl-silanyloxy)-ethyl]-2,2-dimethyl-[1,3]dioxan-4-yl}-ethyl)-3-hydroxy-7-methyl-decahydro-naphthalen-1-yl ester

合成工艺路线路线简述

  • 73573-88-3 = 81093-37-0
    反应条件:1.1 Reagents: Nad,Nadh,Oxygen
    标题:Engineering Of A Hybrid Biotransformation System For Cytochrome P450Sca-2 In Escherichia Coli
    作者:Ba,Lina; Et Al
    参考文献:Biotechnology Journal 日期:2013 卷标:8(7) 页码:785-793
Pravastatin Sodium Salt置于盐酸体系中,用 二氯甲烷,水 作为反应溶剂,以4.54G的收率获得产物普伐他汀
参考文献:他汀含氟衍生物及其用途
标题:他汀含氟衍生物及其用途
摘要:本发明属于药物化学领域,提供了一种3‑羟基‑3‑甲基戊二酞辅酶a还原酶抑制剂,是一种含有3‑氟‑己内酯片段及其内酯开环后形成的3‑氟‑5‑羟基戊酸及其盐或酯的他汀含氟修饰物,其结构式如下这类化合物经测试具有抑制hmg‑coa还原酶活性的效果,可作为新一代的潜在hmg‑coa还原酶抑制剂.

海关参考信息

专利信息


专利号:US-8269001-B2
优先权日:2005-10-05
标题 :Process for the synthesis of HMG-CoA reductase inhibitors
发明人:CASAR ZDENKO
权利人:CASAR ZDENKO; LEK PHARMACEUTICALS
摘要:A novel synthesis of statins uses Wittig reaction of a heterocyclic core of statin with a lactonized side chain already possessing needed stereochemistry. Any separation of diastereoisomers is performed early in the course of synthesis.

专利号:US-10925977-B2
优先权日:2006-10-05
标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

专利号:US-9085538-B2
优先权日:2010-07-26
标题:Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof
发明人:CASAR ZDENKO; STERK DAMJAN; JUKIC MARKO
权利人:CASAR ZDENKO; STERK DAMJAN; JUKIC MARKO; LEK PHARMACEUTICALS
摘要:The invention relates to commercially viable process for the synthesis of key intermediates for the preparation of statins, in particular Rosuvastatin and Pitavastatin or respective pharmaceutically acceptable salts thereof. A new simple and short synthetic route for key intermediates is presented which benefits from the use of cheap and readily available starting materials, by which the conventionally most frequently used DIBAL-H as reducing agent can be avoided.

专利号:US-4739073-A
优先权日:1983-11-04
标题:Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
发明人:KATHAWALA FAIZULLA G
权利人:SANDOZ PHARMACEUTICALS CORP
摘要:Compounds of the formula wherein one of R and Ro is and the other is primary or secondary C1-6alkyl not containing an asymmetric carbon atom, C3-6cycloalkyl or phenyl(CH2)m-, wherein R4 is hydrogen, C1-3alkyl, n-butyl, i-butyl, t-butyl, C1-3alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R5 is hydrogen, C1-3alkyl, C1-3alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R5a is hydrogen, C1-2alkyl, C1-2alkoxy, fluoro or chloro, and m is 1, 2 or 3, with the provisos that both R5 and R5a must be hydrogen when R4 is hydrogen, R5a must be hydrogen when R5 is hydrogen, not more than one of R4 and R5 is trifluoromethyl, not more than one of R4 and R5 is phenoxy, and not more than one of R4 and R5 is benzyloxy, R2 is hydrogen, C1-3alkyl, n-butyl, i-butyl, t-butyl, C3-6cycloalkyl, C1-3alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R3 is hydrogen, C1-3alkyl, C1-3alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, with the provisos that R3 must be hydrogen when R2 is hydrogen, not more than one of R2 and R3 is trifluoromethyl, not more than one of R2 and R3 is phenoxy, and not more than one of R2 and R3 is benzyloxy, X is -(CH2)n- or -CH=CH-, wherein n is 0, 1, 2 or 3, and Z is wherein R6 is hydrogen or C1-3alkyl, and R7 is hydrogen, C1-3alkyl, n-butyl, i-butyl, t-butyl, benzyl or M, wherein M is a pharmaceutically acceptable cation, the use thereof for inhibiting cholesterol biosynthesis and lowering the blood cholesterol level, and, therefore, in the treatment of hyperlipoproteinemia and atherosclerosis, pharmaceutical compositions comprising such compounds and processes for and intermediates in the synthesis of such compounds.

专利号:US-10005720-B2
优先权日:2013-04-05
标题:Compounds useful for the treatment of metabolic disorders and synthesis of the same
发明人:SEXTON JONATHAN Z; BRENMAN JAY E; MUSSO DAVID L
权利人:NORTH CAROLINA CENTRAL UNIV; UNIV NORTH CAROLINA CHAPEL HILL
摘要:The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.

专利号:EP-2017267-A1
优先权日:2007-07-16
标 题:Synthesis of statins
发明人:KOPITAR GREGOR; MRAK PETER; OSLAJ MATEJ
权利人:LEK PHARMACEUTICALS
摘要:The process for synthesis of statins is presented where the intermediate intermediate (4 R ,6 S )-6-(dialkoxymethyl)tetrahydro-2 H -pyran-2,4-diol which already possesses the desired stereochemistry corresponding to final statin is prepared by an aldolaze.
北京中硕医药科技开发有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: https://chinazhongshuo.com/
电话: 13801208576👤
📞北京中硕医药科技开发有限公司 ⚠️参考联系方式

销售电话:13801208576
邮箱:sales@chinazhongshuo.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
珠海蔚蓝医药有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.vitalpharms.com
电话: 0756-3326819👤
📞珠海蔚蓝医药有限公司 ⚠️参考联系方式

销售电话:0756-3326819
邮箱:sales@vitalpharms.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
宁波瑞药新国际贸易有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.risingpharm.com
电话: 86-0378-2295888👤
📞宁波瑞药新国际贸易有限公司 ⚠️参考联系方式

销售电话:86-0378-2295888
邮箱:sales@risingpharm.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页
现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

合成参考文献


参考文献:10.5551/jat.1925
摘要:Aihara K, Miyauchi K, Kasai T, Kubota N, Kajimoto K, Tamura H, Kojima T, Yokoyama K, Kurata T, Amano A, Daida H. Long-term efficacy of pravastatin therapy in diabetic patients undergoing complete coronary revascularization. J Atheroscler Thromb. 2010 Apr 30;17(4):350–5. doi: 10.5551/jat.1925.
参考文献:10.2165/11531530-000000000-00000
摘要:Sawayama Y, Maeda S, Ohnishi H, Hayashi S, Hayashi J. Efficacy and safety of ezetimibe for Japanese patients with dyslipidaemia: The ESSENTIAL Study. Clin Drug Investig. 2010;30(3):157–66. doi: 10.2165/11531530-000000000-00000.
参考文献:10.1016/j.joms.2009.08.027
摘要:Oizumi T, Funayama H, Yamaguchi K, Yokoyama M, Takahashi H, Yamamoto M, Kuroishi T, Kumamoto H, Sasaki K, Kawamura H, Sugawara S, Endo Y. Inhibition of Necrotic Actions of Nitrogen-Containing Bisphosphonates (NBPs) and Their Elimination From Bone by Etidronate (a Non-NBP): A Proposal for Possible Utilization of Etidronate as a Substitution Drug for NBPs. Journal of Oral and Maxillofacial Surgery. 2010 May;68(5):1043–54. doi: 10.1016/j.joms.2009.08.027.
参考文献:10.1007/s11239-010-0457-5
摘要:Campo G, Fileti L, Valgimigli M, Tebaldi M, Cangiano E, Cavazza C, Marchesini J, Ferrari R. Poor response to clopidogrel: current and future options for its management. Journal of Thrombosis and Thrombolysis. 2010 Feb 16;30(3):319–31. doi: 10.1007/s11239-010-0457-5.
参考文献:10.2165/11319380-000000000-00000
摘要:Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf. 2010 Mar 01;33(3):171–87. doi: 10.2165/11319380-000000000-00000.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知